Non Hodgkin Lymphoma Clinical Trial

Idiotype Vaccine for Low-Grade Non-Hodgkin’s Lymphoma

Summary

The purpose of this study was to determine if an idiotype vaccine, made from a patient's lymphoma that has returned after chemotherapy and/or rituximab, would be able to shrink their tumor.

View Full Description

Full Description

The purpose of this study was to assess the ability of active immunotherapy to induce tumor regressions in relapsed low-grade lymphoma. B-cell malignancies express a unique antigen, the immunoglobulin idiotype (Id), on their surface. Each B-cell harbors a unique genetic sequence used in the production of immunoglobulin idiotype. B-cell lymphomas arise from the clonal expansion of a single B-cell and all tumor cells express that unique Id protein. No normal B-cells possess that Id on their cell surface. Hence, Id protein should serve as an ideal target for individualized active immune therapy of NHL. Many of the antigens expressed by tumors (including Id) are only weak immunogens. To augment the immune response against Id, the Id protein must be chemically coupled to a strongly immunogenic protein. Keyhole limpet hemocyanin (KLH) is a commonly used protein carrier capable of augmenting the body's immune reaction against Id protein. While initial studies reported a predominately humoral (antibody) response, cellular immunity (T-cells) also plays a critical role in anti-tumor immunity. GM-CSF is a hematopoietic growth factor that stimulates T-cell proliferation.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria

18 years of age
Histologically confirmed grade 1 or 2 follicular B-cell lymphoma (WHO classification)
Patients that have responded with at least stable disease to their most recent chemo- or anti-CD20 antibody (Rituxan®, Zevalin, Bexxar) therapy for a minimum of 90 days and who currently have relapsed or who continue to have stable disease.
Tumor accessible for biopsy or previously existing biopsy material
At least 1 additional bidimensional lesion measuring at least 2 cm in each dimension
Performance status (ECOG) of 0, 1 or 2
Absolute Granulocyte count ? 1,000/mm3
Total Bilirubin < 2 mg/dL
AST and ALT < 2x Upper Limit of Normal
Creatinine < 1.5 mg/dL

Exclusion Criteria

Patients who have had more than 3 prior chemotherapy or anti-CD20 regimens
Prior fludarabine
Prior tumor-specific idiotype immunotherapy
Patients whose disease has progressed within the first 90 days of their last chemotherapy or anti-CD20 treatment
Concurrent immunosuppressive therapy (high-dose steroids; etc)
Prior splenectomy
Surgery, cancer radiotherapy, steroid therapy, immunotherapy or chemotherapy within 90 days prior to first scheduled vaccination
Known history of CNS lymphoma or meningeal lymphomatosis
HIV positive
Serious non-malignant disease (e.g., psychiatric disorders, congestive heart failure, or active uncontrolled bacterial, viral, or fungal infections), or other conditions which, in the opinion of the investigator would compromise protocol objectives
Prior malignancy (excluding nonmelanoma carcinomas of the skin and in situ cervical carcinomas) unless in remission for > 2 years
Treatment with an investigational drug within 30 days prior to study entry
Pregnant or nursing women NOTE: Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with FavId.

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 2

Estimated Enrollment:

22

Study ID:

NCT00036426

Recruitment Status:

Unknown status

Sponsor:

Favrille

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 12 Locations for this study

See Locations Near You

Scripps Stevens Cancer Center
La Jolla California, 92037, United States
University of California San Diego
La Jolla California, 92093, United States
Tower Hematology Oncology Medical Group
Los Angeles California, 90048, United States
Oncology Associates of San Diego
San Diego California, 92123, United States
Medical Group of North County
Vista California, 92083, United States
University of Florida, Jacksonville
Jacksonville Florida, 32209, United States
Northwestern University
Chicago Illinois, 60611, United States
Henry Ford Hospital
Detroit Michigan, 48202, United States
New York Medical College - Our Lady of Mercy Medical Center, Comprehensive Cancer Center
Bronx New York, 10466, United States
New York Hospital - Cornell Medical Center
New York New York, 10021, United States
Oncology Hematology Care, Inc.
Cincinnati Ohio, 45219, United States
Fox Chase Cancer Center
Philadelphia Pennsylvania, 19111, United States

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 2

Estimated Enrollment:

22

Study ID:

NCT00036426

Recruitment Status:

Unknown status

Sponsor:


Favrille

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider